华润医药,正在“想辙”。撰文| 张烨静华润医药,这家千亿医药巨头,交出了一份归母净利润跌超20%的中报。2025年上半年,华润医药整体表现为增收不增利,其中,总收益达1318.67亿元,同比微增;归母净利润达20.77亿元,同比下降20.25%。剔除短期扰动后,这家医药央企“巨无霸”利润端仍面临结构性压力。值得一提的是,作为华润医药制药版块的“骨干企业”,华润三九中期同样增收不增利,且归母净利润也...
Source Link华润医药,正在“想辙”。撰文| 张烨静华润医药,这家千亿医药巨头,交出了一份归母净利润跌超20%的中报。2025年上半年,华润医药整体表现为增收不增利,其中,总收益达1318.67亿元,同比微增;归母净利润达20.77亿元,同比下降20.25%。剔除短期扰动后,这家医药央企“巨无霸”利润端仍面临结构性压力。值得一提的是,作为华润医药制药版块的“骨干企业”,华润三九中期同样增收不增利,且归母净利润也...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.